A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Mar 16, 2016

Astellas Selected as a Nadeshiko Brand Component for Excellence in Providing Opportunities for Women

- First time for a Pharmaceutical Company to be named to both Diversity Management Selection 100 and Nadeshiko Brand -

Read more about Astellas Selected as a Nadeshiko Brand Component for Excellence in Providing Opportunities for Women
Mar 4, 2016

Astellas Announces Personnel Changes

Read more about Astellas Announces Personnel Changes
Mar 2, 2016

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Mar 1, 2016

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Mar 1, 2016

Astellas Announces Personnel Changes and Organizational Change

Read more about Astellas Announces Personnel Changes and Organizational Change
Mar 1, 2016

Astellas Announces Management Structure Change

Read more about Astellas Announces Management Structure Change
Feb 29, 2016

Astellas Receives Approval for a Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan

Read more about Astellas Receives Approval for a Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan
Feb 24, 2016

Astellas Submits New Drug Application for Linaclotide, Treatment for Irritable Bowel Syndrome with Constipation, in Japan

Tokyo, February 24, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it submitted a new drug application for a guanylate...

Read more about Astellas Submits New Drug Application for Linaclotide, Treatment for Irritable Bowel Syndrome with Constipation, in Japan
Feb 22, 2016

FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Metastatic Castration-resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Versus Bicalutamide

Read more about FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Metastatic Castration-resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Versus Bicalutamide
Feb 10, 2016

Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries

Read more about Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts